1059677-23-4|BPH-715|BPH-715|No data available-范德生物科技公司

BPH-715

NMR下载 COA and HPLC MSDS下载
names：
BPH-715
CAS号：
1059677-23-4
MDL Number： No data available
MF(分子式)： C17H31NO7P2 MW(分子量)： 423.38
EINECS:No data available Reaxys Number:No data available
Pubchem ID:25014899 Brand:BIOFOUNT

BPH-715(1059677-23-4)是新一代的亲脂性双膦酸酯。 BPH-715在细胞培养中有效，并有效抑制肿瘤细胞的生长和侵袭性。 BPH-715被用作阻断蛋白质异戊二烯化的抗癌剂，BPH-715也具有针对疟原虫肝阶段的有效活性。 BPH-715具有抗疟原虫香叶基香叶基二磷酸合酶（GGPPS）的活性，以及对人法呢基和香叶基香叶基二磷酸香叶酯的低nM活性。BPH-715具有抗多种生物的活性，包括血液阶段的疟原虫。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000858-250mg	250mg	>95%	¥ 0.00	¥ 0.00		Backorder	- +	¥ 0.00
YZM000858-100mg	100mg	>95%	¥ 0.00	¥ 0.00		Backorder	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	BPH-715(1059677-23-4);BPH715;BPH 715
英文别名	BPH-715,1059677-23-4
CAS号	1059677-23-4
SMILES	CCCCCCCCCCOC1=C[N+](CC(P(O)(O)=O)P(O)([O-])=O)=CC=C1
Inchi	InChI=1S/C17H31NO7P2/c1-2-3-4-5-6-7-8-9-13-25-16-11-10-12-18(14-16)15-17(26(19,20)21)27(22,23)24/h10-12,14,17H,2-9,13,15H2,1H3,(H3-,19,20,21,22,23,24)
InchiKey	QYJHUOZDBUEKQC-UHFFFAOYSA-N
分子式 Formula	C17H31NO7P2
分子量 Molecular Weight	423.38
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	No data available
密度 Density	No data available
蒸汽压 Vapor Pressure	No data available
溶解度Solubility
性状	Solid
储藏条件 Storage conditions	-20°C Freezer

BPH-715(1059677-23-4)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

BPH-715(1059677-23-4) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:BPH-715(1059677-23-4),BPH-715试剂,BPH-715的纯度,BPH-715抑制剂,BPH-715的杂质,BPH-715的作用,BPH-715的合成,BPH-715的外观,BPH-715的性质,BPH-715的厂家,BPH-715的生产,BPH-715的MSDS,BPH-715的使用

产品说明	BPH-715(1059677-23-4)用作抗癌剂，可阻止蛋白质异戊二烯化，BPH-715也具有针对疟原虫肝阶段的有效活性。
Introduction	BPH-715 (1059677-23-4) is used as an anti-cancer agent to prevent protein prenylation. BPH-715 also has effective activity against the liver stage of Plasmodium.
Application1	BPH715 is used as anticancer agents that block protein prenylation also have potent activity against Plasmodium liver stages.
Application2	BPH715 is also used to treat bone resorption diseases and has activity against a broad range of protists.
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation(Journal of medicinal chemistry,2008)

Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth PMID 20457823; Antimicrobial agents and chemotherapy 2010 Jul; 54(7):2987-93

Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
Singh AP;Zhang Y;No JH;Docampo R;Nussenzweig V;Oldfield E Antimicrob Agents Chemother. 2010 Jul;54(7):2987-93. doi: 10.1128/AAC.00198-10. Epub 2010 May 10.
Abstract:Nitrogen-containing bisphosphonates, drugs used to treat bone resorption diseases, also have activity against a broad range of protists, including blood-stage Plasmodium spp. Here, we show that new-generation "lipophilic" bisphosphonates designed as anticancer agents that block protein prenylation also have potent activity against Plasmodium liver stages, with a high (>100) therapeutic index. Treatment of mice with the bisphosphonate BPH-715 and challenge with Plasmodium berghei sporozoites revealed complete protection (no blood-stage parasites after 28 days). There was also activity against blood-stage forms in vitro and a 4-day delay in the prepatent period in vivo. The lipophilic bisphosphonates have activity against a Plasmodium geranylgeranyl diphosphate synthase (GGPPS), as well as low nM activity against human farnesyl and geranylgeranyl diphosphate synthases. The most active inhibitor in vitro and in vivo had enzyme inhibitory activity similar to that of the other, less active compounds but was more lipophilic. Lipophilic bisphosphonates are thus promising leads for novel antimalarials that target liver-stage infection.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开